Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE We aimed to evaluate the genomic ETV6-RUNX1 fusion sites as a single marker for MRD quantification. 31034759 2019
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017). 31364309 2019
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE Clinical and biological disease characteristics did not differ between the two subgroups of adolescents, including minimal residual disease (MRD) results during initial therapy, except for ETV6-RUNX1 frequency and gender. 31629941 2019
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE Group A showed higher incidence of lymphadenopathy and TEL-AML1 fusion gene than group B. CD304 was reevaluated in group A patients at day 28 postinduction chemotherapy which revealed 12/28 (42.9%) patients with persistent CD304 expression (MRD; group A1) and 16/28 (57.1%) patients who turned CD304 (MRD; group A2). 29200164 2018
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE MRD-positive status was defined as a <4.5-log reduction from diagnosis in <i>RUNX1-RUNX1T1</i> transcripts and/or the loss of a ≥4.5-log reduction after 3 months after HSCT. 30076280 2018
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE In this study, we determined whether RT-qPCR of the ETV6-RUNX1 fusion transcript can be a reliable alternative for MRD analysis. 28004528 2017
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE Patients with t(12;21)/(ETV6-RUNX1) or hyperdiploidy >50 ALL had the best prognosis; those with a negative MRD on day 19 had a particularly low risk of relapse: 1.9% and 3.8%, respectively. 27560110 2017
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE We identified that poor-risk karyotype showed very poor outcome after auto-HCT, and then analyzed 85 patients with good to intermediate-risk molecular cytogenetics with available molecular study results and markers for minimal residual disease (MRD) such as WT1 and core-binding factor (CBF) associated MRD (ie, AML1/ETO and CBFβ/MYH11). 28089879 2017
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE The identification of the genomic sequence of the breakpoint flanking regions of the ETV6-RUNX1 translocation should be the best strategy to monitor minimal residual disease (MRD) in patients with ETV6-RUNX1-positive ALL. 26711002 2016
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE We asked whether minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with the impact of c-KIT mutations. 25082877 2014
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE RUNX1-RUNX1T1 fusion transcript is a well-established marker for minimal residual disease (MRD) monitoring. 24616160 2014
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE Both RT-PCR and RQ-PCR can be used to detect MRD in childhood AML1/ETO AML. 24920269 2014
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE MRD status was the strongest predictor of outcome with 5 year EFS rates greater that 90% seen in those patients with low-risk MRD and this was associated with TEL/AML1 rearrangement, high hyperdiploidy (HH) karyotype and female gender. 23242576 2013
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels. 23535063 2013
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE The fusion gene AML1/ETO is a molecular marker for monitoring minimal residual disease (MRD) in acute myeloid leukemia with the t(8;21)(q22;q22) translocation. 23613269 2013
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g.AML1-ETO, CBFB-MYH11, MLL, FLT-3). 22196957 2012
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE ETV6-RUNX1 was associated with age 1-9 years, pre-treatment classification as low risk and lower levels of minimal residual disease (MRD) on day 19 of therapy (P<0.001). 21869842 2012
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE In core binding factor (CBF) acute myeloid leukaemia (AML), realtime quantitative PCR is useful to quantify the fusion transcript ratio (CBFβ-MYH11 and AML1-ETO, in case of inv(16) and t(8;21) respectively) in peripheral blood and bone marrow during the courses of chemotherapy, in order to monitor minimal residual disease (MRD). 22871474 2012
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE Patients with TEL-AML1 and E2A-PBX1 fusion genes or other B cell precursor ALLs (BCP-ALL) had favorable clinical features, were sensitive to prednisone, had low minimal residual disease (MRD), and an excellent prognosis, with a 5-year event-free survival (EFS) of 84-92%. 22911440 2012
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE To examine the prognostic significance of minimal residual disease (MRD) in t(8;21) acute myeloid leukemia (AML), 96 bone marrow samples from 26 Japanese patients in complete remission (CR) were analyzed regarding the RUNX1/MTG8 transcript using real-time reverse transcriptase polymerase chain reaction assay. 18553224 2008
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE So, persistence of TEL-AML1 fusion as a MRD had no additive prognostic value over its measurement at diagnosis in terms of predicting the probability of OS. 18928518 2008
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 GeneticVariation phenotype BEFREE After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing "best" and "worst" risk groups. 18182569 2008
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 Biomarker phenotype BEFREE Presence of good prognostic markers TEL-AML1 or trisomies of chromosomes 4 and 10 still provided additional prognostic information, but not in National Cancer Institute high-risk (NCI HR) patients who were MRD(+). 18388178 2008
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE Blotting analysis of the levels of the TEL-AML1 fusion transcript was used to detect minimal residual disease. 18635414 2008
Entrez Id: 861
Gene Symbol: RUNX1
RUNX1
0.100 AlteredExpression phenotype BEFREE Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. 12764380 2003